Home Featured 2

Featured 2

Featured posts

Most popular

ICU Care for the Patient with Lung Cancer

lungcanc

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: A Q&A With Dr. Edgardo S. Santos Castillero

$Tackling TKI-Refractory Disease in Patients with Oncogenic Drivers: An Interview with Dr. Mark Socinski$

Tackling TKI-Refractory Disease in Patients with Oncogenic Drivers: An Interview with Dr. Mark Socinski

Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice

Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer

Rebuilding Choice Architecture for Incurable but Treatable Lung Cancer: Rethinking the...

lungcanc

Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?

lungcanc

NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During...

lungcanc

Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About...

lungcanc

Making Headway with Lorlatinib

lungcanc

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

lungcanc

Lung Cancer Pathology Pioneer Dr. Adi Gazdar Dies at 81

lungcanc

PD-L1 in Cytology Specimens

lungcanc

Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

lungcanc

PACIFIC Flooded Us with Optimism. Now What?

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib